The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the fluoroquinolone to the increase in INR (international normalised ratio) is difficult to assess.
Siksi ei ole helppo arvioida fluorokinolonien osuutta INR- arvon (international normalized ratio) nousuun.